摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-chloro-[4-(2-{4-[2-((R)-3-ethoxy-pyrrolidin-1-yl)-2-oxo-ethyl]-piperazin-1-yl}-2-oxo-ethyl)-thiazol-2-yl]-benzamide | 895571-32-1

中文名称
——
中文别名
——
英文名称
4-chloro-[4-(2-{4-[2-((R)-3-ethoxy-pyrrolidin-1-yl)-2-oxo-ethyl]-piperazin-1-yl}-2-oxo-ethyl)-thiazol-2-yl]-benzamide
英文别名
4-chloro-N-[4-[2-[4-[2-[(3R)-3-ethoxypyrrolidin-1-yl]-2-oxoethyl]piperazin-1-yl]-2-oxoethyl]-1,3-thiazol-2-yl]benzamide
4-chloro-[4-(2-{4-[2-((R)-3-ethoxy-pyrrolidin-1-yl)-2-oxo-ethyl]-piperazin-1-yl}-2-oxo-ethyl)-thiazol-2-yl]-benzamide化学式
CAS
895571-32-1
化学式
C24H30ClN5O4S
mdl
——
分子量
520.052
InChiKey
GISDDDKVSXBKJD-HXUWFJFHSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    35
  • 可旋转键数:
    8
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    123
  • 氢给体数:
    1
  • 氢受体数:
    7

文献信息

  • Heteroarylacetamide inhibitors of factor Xa
    申请人:Boehringer Markus
    公开号:US20060142362A1
    公开(公告)日:2006-06-29
    The invention is concerned with novel heteroarylacetamides of formula (I) R d —C(O)—N(R e )—R c —CH 2 —C(O)—N(R a )(R b )   (I) wherein R a to R e are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit the coagulation factor Xa and can be used as medicaments.
    这项发明涉及式(I)的新异杂芳乙酰胺Rd—C(O)—N(Re)—Rc—CH2—C(O)—N(Ra)(Rb),其中Rato Re的定义如描述和索赔中所述,以及其生理上可接受的盐。这些化合物抑制凝血因子Xa,可用作药物。
  • Cyclohexanesulfonyl derivatives as GlyT1 inhibitors to treat schizophrenia
    申请人:Blackaby Peter Wesley
    公开号:US20060276655A1
    公开(公告)日:2006-12-07
    The present invention provides compounds of formula I: wherein R 1 is an alkyl, phenyl, heterocyclyl, cycloalkyl, alkoxy, ester, amino or amide group; R 2 is a phenyl, heterocyclyl, alkyl, cycloalkyl or cycloalkylalkyl group; R 3 is an alkyl, cycloalkyl, cycloalkylalkyl, amino or heterocyclyl group; R 4 and R 5 are hydrogen or alkyl or form a cycloalkyl ring; A is O or N; and m is zero or one; as inhibitors of GlyT1 and thus as useful for treating or preventing diseases such as schizophrenia; with the provision of pharmaceutical compositions, first and second medical uses and methods of treatment.
    本发明提供了化合物的结构如下:其中R1为烷基、苯基、杂环烷基、环烷基、烷氧基、酯基、基或酰胺基;R2为苯基、杂环烷基、烷基、环烷基或环烷基烷基;R3为烷基、环烷基、环烷基烷基、基或杂环烷基;R4和R5为氢或烷基或形成环烷基环;A为氧或氮;m为零或一;作为GlyT1的抑制剂,因此可用于治疗或预防精神分裂症等疾病;并提供了药物组合物、第一和第二医用途以及治疗方法。
  • CYCLOHEXANESULFONYL DERIVATIVES AS GLYT1 INHIBITORS TO TREAT SCHIZOPHRENIA
    申请人:Blackaby Wesley Peter
    公开号:US20100029726A1
    公开(公告)日:2010-02-04
    The present invention provides compounds of formula I: wherein R 1 is an alkyl, phenyl, heterocyclyl, cycloalkyl, alkoxy, ester, amino or amide group; R 2 is a phenyl, heterocyclyl, alkyl, cycloalkyl or cycloalkylalkyl group; R 3 is an alkyl, cycloalkyl, cycloalkylalkyl, amino or heterocyclyl group; R 4 and R 5 are hydrogen or alkyl or form a cycloalkyl ring; A is O or N; and m is zero or one; as inhibitors of GlyT1 and thus as useful for treating or preventing diseases such as schizophrenia; with the provision of pharmaceutical compositions, first and second medical uses and methods of treatment.
    本发明提供了如下式I的化合物: 其中, R1是烷基、苯基、杂环基、环烷基、烷氧基、酯基、基或酰胺基; R2是苯基、杂环基、烷基、环烷基或环烷基烷基; R3是烷基、环烷基、环烷基烷基、基或杂环基; R4和R5是氢、烷基或形成环烷基环; A是O或N; m为零或一。 这些化合物是GlyT1的抑制剂,因此可用于治疗或预防精神分裂症等疾病。同时,还提供了制药组合物、第一和第二医疗用途及治疗方法。
  • HETEROARYLACETAMIDE INHIBITORS OF FACTOR Xa
    申请人:Boehringer Markus
    公开号:US20080146550A1
    公开(公告)日:2008-06-19
    The invention is concerned with novel heteroarylacetamides of formula (I) R—C(O)—N(R e )—R c —CH 2 —C(O)—N(R a )(R b )   (I) wherein R a to R e are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit the coagulation factor Xa and can be used as medicaments.
    这项发明涉及公式(I)的新型杂环基乙酰胺,其中R-C(O)-N(Re)-Rc-CH2-C(O)-N(Ra)(Rb)  (I),其中Ra至Re的定义在说明书和权利要求中,以及其生理上可接受的盐。这些化合物抑制凝血因子Xa,可用作药物。
  • HETEROARYLACETAMIDES AS FACTOR Xa INHIBITORS
    申请人:F.HOFFMANN-LA ROCHE AG
    公开号:EP1846381B1
    公开(公告)日:2008-05-28
查看更多